FDA will not change legacy biologic names

FDA said it no longer intends to retrospectively modify the names of biologics approved without an agency-designated suffix, according to updated draft guidance on the naming of biologics released Thursday.

Under the naming convention, FDA adds a unique four-letter suffix that is devoid of meaning to non-proprietary names of all biologics, including originators and biosimilars. ...